Brief: PhaseBio Announces Bentracimab Phase 2B Trial Data Accepted For Late Breaking Clinical Research Presentation
10/02/2022 13:23
Feb 10 (Reuters) - PhaseBio Pharmaceuticals Inc PHAS.O :
* PHASEBIO ANNOUNCES BENTRACIMAB PHASE 2B TRIAL DATA
ACCEPTED FOR
LATE BREAKING CLINICAL RESEARCH PRESENTATION AT THE 2022
AMERICAN COLLEGE OF CARDIOLOGY (ACC.22) ANNUAL SCIENTIFIC
SESSION
Source text for Eikon: ID:nBwBy2f7a
Further company coverage: PHAS.O
Recent news on PhaseBio Pharmaceuticals
See all newsBrief: Phasebio Pharmaceuticals Says Bankruptcy Court Entered Order Approving 1st Amended Combined Disclosure Statement & Chapter 11 Plan On Final Basis
U.S. RESEARCH ROUNDUP- Entegris, FedEx, Kellogg
U.S. RESEARCH ROUNDUP- Armstrong World Industries, Eli Lilly, Netflix
U.S. STOCKS ON THE MOVE-TransDigm, Vaxcyte, Tricida
PhaseBio Pharma slips on bankruptcy plans